tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Entrada Therapeutics reports progress across development portfolio
PremiumThe FlyEntrada Therapeutics reports progress across development portfolio
1M ago
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion
Premium
Company Announcements
Entrada Therapeutics Reports Increased Losses Amid R&D Expansion
3M ago
Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital
Premium
The Fly
Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital
3M ago
Entrada Therapeutics: Undervalued Leader in RNA Therapeutics with Promising DMD Pipeline
PremiumRatingsEntrada Therapeutics: Undervalued Leader in RNA Therapeutics with Promising DMD Pipeline
4M ago
3 Best Stocks to Buy Now, 10/24/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 10/24/2025, According to Top Analysts
4M ago
Entrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Premium
The Fly
Entrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
5M ago
Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
PremiumThe FlyEntrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
6M ago
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting
Premium
Company Announcements
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting
8M ago
Entrada Therapeutics Appoints New Board Member
Premium
Company Announcements
Entrada Therapeutics Appoints New Board Member
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100